An observational study in Type 2 Diabetes Mellitus (T2DM), sponsored by University Hospital, Ghent. Recruiting at 2 sites in Belgium. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by University Hospital, Ghent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium — 13 open to participants now, 19 under way, 5 of them phase 3. Diabetes Mellitus, Type 2 · Belgium.
Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, this one is the 16th largest by planned enrollment of the 18 observational ones that give a count, is one of 3 that started in 2026, is one of 18 observational ones, reaches primary completion later than 11 of the 18 other live ones, and was the 141st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 8 more countries
Ages 10–17
Novo Nordisk A/S · Sites in Belgium, United States, Argentina and 16 more countries
Ages 18+
Universiteit Antwerpen · Sites in Belgium
Ages 60+
Boehringer Ingelheim · Sites in Belgium, United States, Argentina and 48 more countries
Ages 18+
University Ghent · Sites in Belgium
Ages 20–30
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 79 · Phase 4 10
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 504 across the 131 interventional studies, 759 across the 18 observational. Of the 126 that completed or were terminated, 69 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 149 have an industry lead sponsor. The 10 most frequent:
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
University Hospital, Ghent has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04993482University Hospital, Ghent24-hour Movement Behaviors Among Type 2 Diabetes Mellitus Patients | 2026-12-01 |
| NCT07257822KU LeuvenThe Digital Diabetes Patient Reminder (DIPAR) Tool For Adults With Type 2 Diabetes | 2027-06 |
| NCT07786194Universiteit AntwerpenImprovement Through Movement - Balance Control and Somatosensory Function in People With Diabetes Mellitus Type 2 | 2027-07-31 |
| NCT06734546Hasselt UniversityThe Effect of Exercise on the Brain in Type 2 Diabetes | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).
Flemish T2DM patients and controls from Ghent region.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
persons with type 2 diabetes mellitus
Dietary Supplement: Oral Polyphenol Challenge Test / PPPIL · Diagnostic Test: fasting blood sample · Diagnostic Test: Fasting urine collection · Diagnostic Test: 24 hours urine collection · Other: Questionnaires · Diagnostic Test: Stool collection · Diagnostic Test: Transit time determination
This cohort is a group without type 2 diabetes or any other chronic illness
Dietary Supplement: Oral Polyphenol Challenge Test / PPPIL · Diagnostic Test: fasting blood sample · Diagnostic Test: Fasting urine collection · Diagnostic Test: 24 hours urine collection · Other: Questionnaires · Diagnostic Test: Stool collection · Diagnostic Test: Transit time determination
Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)
Fasting blood sample will be obtained for determination of markers of metabolic health.
Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites
Subjects collect urine over the entire 24h. for determination of polyphenol metabolites
Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.
Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.
Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.
Differences in polyphenol metabolites in morning urine in persons with type 2 diabetes and in healthy controls.
The study aims to characterize the overall polyphenol metabotype in patients with T2DM compared to age-matched individuals without diabetes. For this purpose we will look at morning urine 24h after ingestion of a polyphenol rich pill.
Time frame: This will be assessed the morning after ingestion of the pill containing polyphenols
Differences in polyphenol metabolites in 24h urine in persons with type 2 diabetes and in healthy controls.
For this purpose participants will collect urine over a 24h period
Time frame: Urine will be collected over a 24h period after ingestion of the polyphenol pill.
Transit time
Along with the ingestion of the polyphenol pill, people will consume E133, a food colorant that will also color the stool.
Time frame: baseline
the capacity of the gut microbiome to degrade polyphenols
By using a batch experiment.
Time frame: baseline
Metabolic health
This will be determined on the fasting blood samples
Time frame: baseline
lifestyle factors and medical history (A)
physical activity, using the validated IPAQ questionnaire
Time frame: baseline
lifestyle factors and medical history (B)
Sleep, using the validated PSQI questionnaire
Time frame: baseline
Plan to share: Yes — All anonymous data will be made available on request after publication also to other researchers.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Nov 2028, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.